Oncology

Immunotherapy combined with standard neoadjuvant chemotherapy has shown encouraging benefits in hormone receptor positive, HER2 negative early breast cancer, according to new evidence.

The addition of nivolumab to platinum-etoposide chemotherapy improved both progression-free and overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC), according to results from the randomized Phase II ECOG-ACRIN EA5161 trial.

Frequent ibuprofen use was associated with a reduced risk of endometrial cancer, while aspirin showed no measurable effect, according to a large cohort analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pediatric central nervous system (CNS) tumors remain among the most fatal childhood cancers, largely because the blood-brain barrier (BBB) restricts effective therapeutic delivery and worsens clinical outcomes.

A Phase I trial of a pancreatic cancer vaccine targeting mutant KRAS has demonstrated durable immune responses and promising survival outcomes in patients with minimal residual disease following standard treatment.

A large population-based case–control study has found that a history of malignant melanoma (MM) does not increase the likelihood of developing vitiligo in the general population, with a notable exception in the Arab minority.

Patients with psoriasis initiating biologic therapy, particularly tumor necrosis factor (TNF) inhibitors, may have a reduced long-term risk of developing primary malignancies compared with biologic-naïve individuals, according to a large retrospective cohort study.

Interstitial lung disease (ILD) is independently associated with a significantly higher risk of developing lung cancer, according to new findings from a large population-based cohort study that controlled for genetic factors.